ARVINAS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARVINAS, INC. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $334.20M.
- ARVINAS, INC. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $36.00M.
- ARVINAS, INC. stock issued during period, value, new issues for the quarter ending 2021-12-31 was $0.00.
- ARVINAS, INC. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $259.90M.
- ARVINAS, INC. stock issued during period, value, new issues for fiscal 2023 was $370.20M.
- ARVINAS, INC. stock issued during period, value, new issues for fiscal 2021 was $259.90M, a 39.82% decline from fiscal 2020.
- ARVINAS, INC. stock issued during period, value, new issues for fiscal 2020 was $431.90M, a 215.03% increase from fiscal 2019.
- ARVINAS, INC. stock issued during period, value, new issues for fiscal 2019 was $137.10M, a 23.34% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $334.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $370.20M 10-K · filed 2026-02-24 |
| 2023-09-30 | $36.00M 10-Q · filed 2024-10-30 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $259.90M 10-K · filed 2024-02-27 |
| 2021-09-30 | $259.90M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $431.90M 10-K · filed 2023-02-23 | |
| 2019-12-31 | $107.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $137.10M 10-K · filed 2022-02-28 |
| 2019-09-30 | $29.45M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $111.16M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |